Merus is financed by blue chip financial and strategic investors, including Bay City Capital, LSP, Aglaia Oncology Fund, Novartis Venture Funds and Pfizer Venture Investments. The expertise and financial scale of these investors position Merus as a leading company in the development of next generation antibody therapeutics. To date the company has raised more than Euro 30 million in venture capital and public funding.
